Inflammatory profiles define phenotypes with clinical relevance in acute type A aortic dissection

Association of distinct inflammatory profiles with short-term mortality is little known in type A aortic dissection (TAAD). Latent class analysis was used to identify distinct inflammatory profiles based on leukocyte, neutrophils, monocyte, lymphocytes, platelet, fibrinogen, d -dimer, neutrophils-ly...

Full description

Saved in:
Bibliographic Details
Published inJournal of cardiovascular translational research Vol. 16; no. 6; pp. 1383 - 1391
Main Authors Zhao, Hong-lei, Tang, Zhi-wei, Diao, Yi-fei, Xu, Xiu-fan, Qian, Si-chong, Li, Hai-yang, Shao, Yong-feng, Zhao, Sheng, Liu, Hong
Format Journal Article
LanguageEnglish
Published New York Springer US 01.12.2023
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Association of distinct inflammatory profiles with short-term mortality is little known in type A aortic dissection (TAAD). Latent class analysis was used to identify distinct inflammatory profiles based on leukocyte, neutrophils, monocyte, lymphocytes, platelet, fibrinogen, d -dimer, neutrophils-lymphocyte ratio, platelet-lymphocyte ratio, and lymphocyte-monocyte ratio. We identified 193 patients with median age of 56 (IQR 47–63) years and 146 males. Patients were divided as hyper-inflammatory profiles (84 [43.5%]) and hypo-inflammatory profiles (109 [56.5%]). Although baseline characteristics were not different, hyper-inflammatory patients had higher 6-month mortality (20 [23.8%] vs. 11 [10.1%]; P  = 0.014) and 30-day mortality (18 [21.4%] vs. 9 [8.3%], P  = 0.009) than hypo-inflammatory patients. After adjustment for potential confounders, hyper-inflammatory profiles remain associated with higher risk of 6-month mortality than hypo-inflammatory profiles (adjusted OR 2.427 [95%CI 1.154, 5.105], P  = 0.019). Assessment of preoperative inflammatory profiles adds clarity regarding the extent of inflammatory response to TAAD aetiopathologies, highlighting individual anti-inflammatory pharmacotherapy for TAAD. ClinicalTrials.gov Identifier: NCT04398992. Graphical Abstract
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1937-5387
1937-5395
1937-5395
DOI:10.1007/s12265-023-10436-z